178 related articles for article (PubMed ID: 33436083)
1. Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.
Grit JL; Johnson BK; Dischinger PS; J Essenburg C; Adams M; Campbell S; Pollard K; Pratilas CA; Triche TJ; Graveel CR; Steensma MR
Epigenetics Chromatin; 2021 Jan; 14(1):7. PubMed ID: 33436083
[TBL] [Abstract][Full Text] [Related]
2. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
3. Identification of potential common genetic modifiers of neurofibromas: a genome-wide association study in 1333 patients with neurofibromatosis type 1.
Pacot L; Sabbagh A; Sohier P; Hadjadj D; Ye M; Boland-Auge A; Bacq-Daian D; Laurendeau I; Briand-Suleau A; Deleuze JF; Margueron R; Vidaud M; Ferkal S; Parfait B; Vidaud D; ; Pasmant E; Wolkenstein P
Br J Dermatol; 2024 Jan; 190(2):226-243. PubMed ID: 37831592
[TBL] [Abstract][Full Text] [Related]
4. Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.
Banerjee J; Allaway RJ; Taroni JN; Baker A; Zhang X; Moon CI; Pratilas CA; Blakeley JO; Guinney J; Hirbe A; Greene CS; Gosline SJ
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32098059
[TBL] [Abstract][Full Text] [Related]
5. Modeling tumors of the peripheral nervous system associated with Neurofibromatosis type 1: Reprogramming plexiform neurofibroma cells.
Mazuelas H; Carrió M; Serra E
Stem Cell Res; 2020 Dec; 49():102068. PubMed ID: 33160273
[TBL] [Abstract][Full Text] [Related]
6. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas.
Kluwe L; Friedrich RE; Korf B; Fahsold R; Mautner VF
Hum Mutat; 2002 Mar; 19(3):309. PubMed ID: 11857752
[TBL] [Abstract][Full Text] [Related]
7. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1.
Pasmant E; Sabbagh A; Masliah-Planchon J; Ortonne N; Laurendeau I; Melin L; Ferkal S; Hernandez L; Leroy K; Valeyrie-Allanore L; Parfait B; Vidaud D; Bièche I; Lantieri L; Wolkenstein P; Vidaud M;
J Natl Cancer Inst; 2011 Nov; 103(22):1713-22. PubMed ID: 22034633
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1.
Jiang C; McKay RM; Lee SY; Romo CG; Blakeley JO; Haniffa M; Serra E; Steensma MR; Largaespada D; Le LQ
J Invest Dermatol; 2023 Aug; 143(8):1369-1377. PubMed ID: 37318402
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.
Carrió M; Mazuelas H; Richaud-Patin Y; Gel B; Terribas E; Rosas I; Jimenez-Delgado S; Biayna J; Vendredy L; Blanco I; Castellanos E; Lázaro C; Raya Á; Serra E
Stem Cell Reports; 2019 Feb; 12(2):411-426. PubMed ID: 30713041
[TBL] [Abstract][Full Text] [Related]
10. TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.
Park GH; Lee SJ; Yim H; Han JH; Kim HJ; Sohn YB; Ko JM; Jeong SY
Oncol Rep; 2014 Oct; 32(4):1347-54. PubMed ID: 25109740
[TBL] [Abstract][Full Text] [Related]
11. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings.
Carrió M; Gel B; Terribas E; Zucchiatti AC; Moliné T; Rosas I; Teulé Á; Ramón Y Cajal S; López-Gutiérrez JC; Blanco I; Castellanos E; Lázaro C; Stemmer-Rachamimov A; Romagosa C; Serra E
Hum Mutat; 2018 Aug; 39(8):1112-1125. PubMed ID: 29774626
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis.
Lévy P; Bièche I; Leroy K; Parfait B; Wechsler J; Laurendeau I; Wolkenstein P; Vidaud M; Vidaud D
Clin Cancer Res; 2004 Jun; 10(11):3763-71. PubMed ID: 15173083
[TBL] [Abstract][Full Text] [Related]
13. Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
Flint AC; Mitchell DK; Angus SP; Smith AE; Bessler W; Jiang L; Mang H; Li X; Lu Q; Rodriguez B; Sandusky GE; Masters AR; Zhang C; Dang P; Koenig J; Johnson GL; Shen W; Liu J; Aggarwal A; Donoho GP; Willard MD; Bhagwat SV; Clapp DW; Rhodes SD
Clin Cancer Res; 2023 Sep; 29(17):3438-3456. PubMed ID: 37406085
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis.
Masliah-Planchon J; Pasmant E; Luscan A; Laurendeau I; Ortonne N; Hivelin M; Varin J; Valeyrie-Allanore L; Dumaine V; Lantieri L; Leroy K; Parfait B; Wolkenstein P; Vidaud M; Vidaud D; Bièche I
BMC Genomics; 2013 Jul; 14():473. PubMed ID: 23848554
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.
Lévy P; Vidaud D; Leroy K; Laurendeau I; Wechsler J; Bolasco G; Parfait B; Wolkenstein P; Vidaud M; Bièche I
Mol Cancer; 2004 Jul; 3():20. PubMed ID: 15255999
[TBL] [Abstract][Full Text] [Related]
16. Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study.
Basto DL; de Souza Vieira G; Andrade-Losso RM; Almeida PN; Riccardi VM; Rozza-de-Menezes RE; Cunha KS
Orphanet J Rare Dis; 2022 Sep; 17(1):341. PubMed ID: 36064430
[TBL] [Abstract][Full Text] [Related]
17. Expression of Ras signaling pathway proteins and developmental factors in peripheral nerve sheath tumors of patients with neurofibromatosis type 1.
Hagel C; Nörnberg LKN; Friedrich RE
Clin Neuropathol; 2023; 42(4):150-160. PubMed ID: 37226590
[TBL] [Abstract][Full Text] [Related]
18. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells.
Ferrer M; Gosline SJC; Stathis M; Zhang X; Guo X; Guha R; Ryman DA; Wallace MR; Kasch-Semenza L; Hao H; Ingersoll R; Mohr D; Thomas C; Verma S; Guinney J; Blakeley JO
Sci Data; 2018 Jun; 5():180106. PubMed ID: 29893754
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
